DermTech Balance Sheet Health
Financial Health criteria checks 4/6
DermTech has a total shareholder equity of $57.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $121.9M and $64.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$55.86m |
| Equity | US$57.18m |
| Total liabilities | US$64.76m |
| Total assets | US$121.93m |
Recent financial health updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02
Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11Recent updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27Financial Position Analysis
Short Term Liabilities: DMTK's short term assets ($61.8M) exceed its short term liabilities ($13.4M).
Long Term Liabilities: DMTK's short term assets ($61.8M) exceed its long term liabilities ($51.3M).
Debt to Equity History and Analysis
Debt Level: DMTK is debt free.
Reducing Debt: DMTK currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DMTK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DMTK has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.4% each year